Boston Scientific(US:BSX) Businesswire·2026-03-05 23:56Core Viewpoint - Robbins LLP has announced a class action lawsuit against Boston Scientific Corporation, alleging that the company misled investors regarding its projected revenue and growth potential during the specified class period [1]. Group 1: Allegations and Company Performance - The lawsuit claims that Boston Scientific created a false impression of having reliable information about its revenue outlook while downplaying risks from seasonality and macroeconomic factors [1]. - The company aimed to grow its share in the electrophysiology (EP) market at a rate of "2x the market," but faced new competition that negatively impacted its U.S. EP market share and growth potential [1]. - On February 4, 2026, Boston Scientific reported disappointing fourth quarter and full year 2025 results, particularly in U.S. EP sales, and provided guidance for fiscal 2026 that was significantly below expectations [1]. Group 2: Stock Price Impact - Following the announcement of disappointing results and guidance, Boston Scientific's stock price fell over 17%, dropping from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026 [1].